Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;124(10):4223-6.
doi: 10.1172/JCI78371. Epub 2014 Sep 9.

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight

Laurie L Baggio et al. J Clin Invest. 2014 Oct.

Abstract

The peptide hormone glucagon-like peptide-1 (GLP-1) enhances glucose-induced insulin secretion and inhibits both gastric emptying and glucagon secretion. GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals. Nevertheless, the mechanisms and cellular targets transducing the weight loss effects remain unclear. Two recent studies in the JCI provide insight into the neurons responsible for this effect. Sisley et al. reveal that GLP-1R agonist-induced weight loss requires GLP-1Rs in the CNS, while Secher et al. reveal that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. Together, these two studies elucidate pathways that inform strategies coupling GLP-1R signaling to control of body weight in patients with diabetes or obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Peripherally administered GLP-1R agonists reduce food intake and body weight through signaling mechanisms requiring functional GLP-1Rs in the ARC of the hypothalamus.
Several regions of the brain express GLP-1Rs, including the ARC, PVN, and subfornical organ (SFO), and signals from GLP-1 are transmitted through the vagus nerve or converge on the NTS and area postrema (AP). GLP-1 directly activates POMC/CART neurons and indirectly inhibits, via GABAergic transmission, the neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons, which collectively results in signals that reduce food intake. Although GLP-1 generates signals that are transmitted through the vagus nerve or converge on the NTS or PVN of the hypothalamus (Hyp), these regions are not required to transduce an anorectic GLP-1R–dependent signal.

Comment on

References

    1. Campbell JE, Drucker DJ. Pharmacology physiology and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. doi: 10.1016/j.cmet.2013.04.008. - DOI - PubMed
    1. Meeran K, et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology. 1999;140(1):244–250. - PubMed
    1. Barrera JG, Sandoval DA, D’Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol. 2011;7(9):507–516. doi: 10.1038/nrendo.2011.77. - DOI - PMC - PubMed
    1. Patterson JT, et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol. 2011;6(2):135–145. doi: 10.1021/cb1002015. - DOI - PubMed
    1. Steinert RE, et al. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr. 2014;100(2):514–523. doi: 10.3945/ajcn.114.083246. - DOI - PubMed